• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

ChromoGenics AB (publ): ChromoGenics communicates order data for the fourth quarter in 2023 and postpones publication of the year-end report for 2023.

ChromoGenicsRegulatory press release16.02.2024, 16.00
Discuss
Download the release

ChromoGenics order intake for the fourth quarter 2023 amounted to 6,6 MSEK and the order book for the same period was 11,5 MSEK.

Due to unexpected administrative reasons, the Board of Directors of ChromoGenics has decided to postpone the publication of the year-end report for 2023 until 8[th] of March 2024. Previously communicated date for submission of the report was on the 20[th] of February 2024.

Full data on the fourth quarter 2023 will be published in the year-end report.

Contact:

Fredrik Fränding, CEO
Anne-Marie Gullman, CFO & Head of Investor Relations
Tel: +46 (0) 18 430 0430

E-mail: info@chromogenics.com